scholarly journals Let-7a inhibits migration, invasion and tumor growth by targeting AKT2 in papillary thyroid carcinoma

Oncotarget ◽  
2017 ◽  
Vol 8 (41) ◽  
pp. 69746-69755 ◽  
Author(s):  
Bin Zhou ◽  
Hailin Shan ◽  
Ying Su ◽  
Kai Xia ◽  
Runlong Zou ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Tumor Growth ◽  
Papillary Thyroid

miR-182 targets CHL1 and controls tumor growth and invasion in papillary thyroid carcinoma

2014 ◽  
Vol 450 (1) ◽  
pp. 857-862 ◽  
Author(s):  
Hongling Zhu ◽  
Jin Fang ◽  
Jichen Zhang ◽  
Zefei Zhao ◽  
Lianyong Liu ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Tumor Growth ◽  
Papillary Thyroid ◽  
Tumor Growth And Invasion

scholarly journals Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma

2010 ◽  
Vol 23 (9) ◽  
pp. 1201-1208 ◽  
Author(s):  
Chan-Kwon Jung ◽  
Yoon-Goo Kang ◽  
Ja-Seong Bae ◽  
Dong-Jun Lim ◽  
Yeong-Jin Choi ◽  
...  
Keyword(s):  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Lymph Node Metastasis ◽  
Thyroid Carcinoma ◽  
Tumor Growth ◽  
Papillary Thyroid ◽  
Node Metastasis

Characteristic tumor growth patterns as novel histomorphologic predictors for lymph node metastasis in papillary thyroid carcinoma

2013 ◽  
Vol 44 (12) ◽  
pp. 2620-2627 ◽  
Author(s):  
Yoon Yang Jung ◽  
Chung Hun Lee ◽  
So Yeon Park ◽  
Hyo Jin Park ◽  
Hye Sook Min ◽  
...  
Keyword(s):  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Lymph Node Metastasis ◽  
Thyroid Carcinoma ◽  
Tumor Growth ◽  
Growth Patterns ◽  
Papillary Thyroid ◽  
Node Metastasis

scholarly journals PBX3 Promotes Tumor Growth and Angiogenesis via Activation of AT1R/VEGFR2 Pathway in Papillary Thyroid Carcinoma

2020 ◽  
Vol 2020 ◽  
pp. 1-10 ◽  
Author(s):  
Qin Chen ◽  
Wen-Ying Yu ◽  
Huan-Huan Zhang ◽  
Song-Zhao Zhang ◽  
Jie Fang ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Tumor Growth ◽  
Papillary Thyroid ◽  
Normal Tissues ◽  
Cycle Arrest ◽  
B Cell Leukemia

PBX3 (Pre-B-cell leukemia homeobox 3) had been considered to be a multifunctional oncogene which involved in tumor growth, invasion, and metastasis in leukemia and some solid tumors. However, the contribution of PBX3 to papillary thyroid carcinoma (PTC) remains unclear. In this study, we found that PBX3 expression was significantly upregulated in PTC tissues compared to adjacent normal tissues, and high levels of PBX3 were correlated with tumor size, lymphatic metastasis, TMN stage, and poor prognosis of PTC patients. Overexpression of PBX3 in PTC cell lines promoted cell proliferation. Consistently, knockdown of PBX3 by shRNA induced cell cycle arrest at G0/G1 phase, and inhibited angiogenesis and tumor growth in vitro and in vivo. Furthermore, PBX3 promoted PTC cell proliferation and angiogenesis through activation of AT1R/VEGFR2 pathway while overexpression of AT1R and treatment with VEGFA reversed PBX3-shRNA-induced decreased phosphorylation of VEGFR2 and its downstream (ERK1/2, AKT and Src). It demonstrated that PBX3 could be used as a potential prognostic biomarker and therapeutic target for PTC.

scholarly journals Tumor Volume Kinetic Analyses Might Explain Excellent Prognoses in Young Patients with Papillary Thyroid Carcinoma

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Toshihiko Kasahara ◽  
Akira Miyauchi ◽  
Yasuhiro Ito ◽  
Takumi Kudo ◽  
Hiroo Masuoka ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Tumor Growth ◽  
Cancer Cell ◽  
Tumor Volume ◽  
Advanced Disease ◽  
Young Patients ◽  
Papillary Thyroid ◽  
Volume Doubling ◽  
Single Cancer

Introduction. Young patients with papillary thyroid carcinoma (PTC) generally have excellent prognoses despite their often-advanced disease status. The reasons for this excellent prognosis are poorly understood. Objective. To investigate the natural history of PTC in young patients, we compared the observed tumor volume-doubling rate (TV-DR) with the hypothetical tumor volume-doubling rate (hTV-DR) before presentation in young PTC patients. DR is an inverse of the doubling time and indicates the number of doublings that occur in a unit of time. A negative value indicates the number of times the volume is reduced by half per unit time. Methods. We enrolled 20 patients with the following characteristics: age ≤19 years, diagnosed with PTC according to the cytology results between 2013 and 2018 and followed-up with periodical ultrasound examinations for ≥3 months before surgery for various reasons. Seventeen patients later underwent surgery confirming the diagnosis. We calculated TV-DRs using serial measurements of tumor diameters after presentation and hTV-DRs using tumor diameters and patients’ age at presentation, assuming that a single cancer cell was present at the patient’s birth and that the tumor grew at a constant rate. These values indicate the lowest growth rates necessary for a single cancer cell to achieve the full tumor size at presentation. Results. Thirteen patients had positive TV-DRs (/year) ranging from 0.09 to 1.89, indicating tumor growth, and the remaining seven patients had negative values (−0.08 to −1.21), indicating regression. The median TV-DR was 0.29. The hTV-DRs (1.48–2.66, median 1.71) were significantly larger than the TV-DRs (p<0.001), indicating much faster growth before presentation. Conclusions. These data suggest that deceleration of tumor growth had already occurred at presentation in the majority of the cases. This might explain why disease-specific survival is excellent despite frequent findings of advanced disease in young patients with PTC.

scholarly journals Adenovirus-mediated siRNA targeting NOB1 inhibits tumor growth and enhances radiosensitivity of human papillary thyroid carcinoma in vitro and in vivo

2014 ◽  
Vol 32 (6) ◽  
pp. 2411-2420 ◽  
Author(s):  
WEI MENG ◽  
PEI-SONG WANG ◽  
JIA LIU ◽  
SHUAI XUE ◽  
GUI-MIN WANG ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Tumor Growth ◽  
Papillary Thyroid
Sign in / Sign up

Export Citation Format

Share Document